NEKTAR THERAPEUTICS
corporate_fare Company Profile
NEKTAR THERAPEUTICS (NASDAQ:NKTR) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for NKTR at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 9 rated 8 or above. Recent SEC coverage for NKTR spans 8-K, 10-Q, 424B5, DEFA14A.
Recent high-impact activity:
- Nektar Posts $55.7M Q3 Loss, EPS of -$1.63 as Product Sales Reach $9.4M
- Nektar Sinks 19% Despite Durable Hair Loss Data; Analysts See Positive Read-Through for Q32 Bio
- Rezpegaldesleukin Demonstrates Durable Hair Regrowth Six Months After Treatment Cessation in Phase 2b Alopecia Areata Study
- Rezpeg Shows Durable Response at One Year, Phase 3 AA Trial Set for Early 2027
- Nektar Secures $90M Jury Verdict Against Eli Lilly in Rezpeg License Dispute
Financial Snapshot
Short Interest & Short Volume
10.26 days to coverFINRA reported short interest of 6,766,027 shares in NKTR as of the October 30, 2026 settlement, a 3.3% decrease from the prior period — about 10.3 days to cover at its recent average daily volume. On November 19, 2026, 63.7% of NKTR volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for NKTR, detected from its recent SEC filings · based on capital-structure filings through 2026-06-05.
Share Incentive Plan Expansion Approved · Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →